MRKR Marker Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MRKR

Price (delayed)

$1.22

Market cap

$20.34M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.61

Enterprise value

$4.7M

?
Relative Growth: Rel. Growth: 29
Relative Strength: Rel. Strength: 28
Relative Valuation: Rel. Valuation: 10
Relative Profitability: Rel. Profitability: 32

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy ...

Highlights
The EPS has soared by 54% year-on-year and by 23% since the previous quarter
MRKR's net income is up by 15% year-on-year and by 10% since the previous quarter
Marker Therapeutics's quick ratio has decreased by 42% from the previous quarter and by 28% YoY
MRKR's revenue is down by 40% year-on-year and by 10% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://markertherapeutics.com
Peers: VIVS ORIC ORMP

Key stats

What are the main financial stats of MRKR

MRKR stock price

How has the Marker Therapeutics stock price performed over time
Intraday
-3.94%
1 week
-6.87%
1 month
-6.87%
1 year
-18.67%
YTD
-18.12%
QTD
-17.01%

Financial performance

How have Marker Therapeutics's revenue and profit performed over time
Revenue
$3.2M
Gross profit
$3.2M
Operating income
-$12.35M
Net income
-$10.9M
Gross margin
100%
Net margin
-340.8%
MRKR's operating margin has dropped by 53% year-on-year and by 6% since the previous quarter
The company's net margin fell by 43% YoY
MRKR's revenue is down by 40% year-on-year and by 10% since the previous quarter
Marker Therapeutics's gross profit has decreased by 40% YoY and by 10% QoQ

Price vs fundamentals

How does MRKR's price correlate with its fundamentals

Growth

What is Marker Therapeutics's growth rate over time

Valuation

What is Marker Therapeutics stock price valuation
P/E
N/A
P/B
1.47
P/S
7.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.47
The EPS has soared by 54% year-on-year and by 23% since the previous quarter
The P/B is 23% below the 5-year quarterly average of 1.9 but 13% above the last 4 quarters average of 1.3
Marker Therapeutics's equity has decreased by 18% from the previous quarter and by 4.8% YoY
MRKR's revenue is down by 40% year-on-year and by 10% since the previous quarter
MRKR's P/S is 34% above its last 4 quarters average of 5.5 but 31% below its 5-year quarterly average of 10.7

Efficiency

How efficient is Marker Therapeutics business performance
The ROS is down by 43% year-on-year
The ROE is up by 28% year-on-year and by 9% since the previous quarter
The ROA has grown by 28% YoY and by 11% from the previous quarter

Dividends

What is MRKR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRKR.

Financial health

How did Marker Therapeutics financials performed over time
MRKR's total liabilities has surged by 60% since the previous quarter and by 45% year-on-year
The current ratio has contracted by 43% from the previous quarter and by 29% YoY
The company's debt is 100% lower than its equity
Marker Therapeutics's equity has decreased by 18% from the previous quarter and by 4.8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.